(Q34604680)

3 August 2017

0 references

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis (English)

1 reference

3 August 2017

0 references

William J Elliott

1 reference

3 August 2017

Peter M Meyer

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

369

1 reference

3 August 2017

issue

9557

1 reference

3 August 2017

page(s)

201-207

1 reference

New drugs for the treatment of hypertension

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Aggravation of diabetes mellitus during treatment with chlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

DIABETOGENIC ACTION OF BENZOTHIADIAZINES: SERUM-INSULIN-LIKE ACTIVITY IN DIABETES WORSENED OR PRECIPITATED BY THIAZIDE DIURETICS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Drug-induced hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Antihypertensive medications and the risk of incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Old antihypertensives and new diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Antihypertensive therapy and incidence of type 2 diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

A systematic review of drug therapy to delay or prevent type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Differential effects of antihypertensive drugs on new-onset diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Feasibility of treating prehypertension with an angiotensin-receptor blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

The verdict from ALLHAT--thiazide diuretics are the preferred initial therapy for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Recent trials in hypertension: compelling science or commercial speech?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Preventing type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Predictive Properties of Impaired Glucose Tolerance for Cardiovascular Risk Are Not Explained by the Development of Overt Diabetes During Follow-Up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960108-1

7 January 2021

10.1016/S0140-6736(07)60108-1

Identifiers

DOI

1 reference

3 August 2017

1 reference